Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacosamide - UCB

Drug Profile

Lacosamide - UCB

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; Duke University; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine gated NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Phase II/III Epilepsy
  • Phase II Seizures
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 29 Oct 2019 UCB Pharma completes a compassionate-use-programme for Partial epilepsies (In adolescents, In adults, In the elderly) (NCT03559673)
  • 31 Jul 2019 UCB Pharma completes a phase III extension trial in (Partial epilepsies (Adjunctive treatment, In adolescents, In children, In adults, In the elderly) in China and Japan (NCT01832038)
  • 24 Jul 2019 UCB Pharma plans to submit regulatory applications for Generalised seizures in the first half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top